Biogen preclinical data

BGEN researchers and colleagues published in Nature Medicine and the Proceedings of the National Academy of Sciences two preclinical studies demonstrating that treatment with Antova prevented rejection of donor tissue.

In a study of 13 rhesus monkeys undergoing kidney transplantation, 0 of 9 that were treated with Antova alone experienced a rejection episode, while all 4 untreated control monkeys lost their grafts to acute rejection. The researchers noted that the effect persisted up to 10 months after therapy termination, and the use of additional drugs such as tacrolimus or steroids actually antagonized the effect. Antova is in Phase II testing in renal transplantation. ...